University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Amy M. Lin

Amy M. Lin, M.D.

Genitourinary cancer specialist

Dr. Amy Lin is a genitourinary cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center. Her research focuses on screening tests and treatments for prostate cancer. She also treats kidney and urothelial cancer.

She earned a medical degree at the UCLA School of Medicine, completed a residency in internal medicine at New York Presbyterian Hospital and completed fellowships in hematology, oncology and urologic oncology at UCSF. She is an assistant professor of medicine in the division of hematology and oncology at UCSF.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Amy M. Lin

Education

UCLA School of Medicine 1999

Residencies

New York Presbyterian Hospital, Internal Medicine 2002

Fellowships

UCSF Medical Center, Hematology Oncology 2005

Selected Research and Publications

  1. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
  2. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90.
  3. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
  4. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
  5. Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9.
  6. Lin AM, Small EJ. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91.
  7. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8.
  8. Lin AM, Small EJ. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33.
  9. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54.
  10. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9.
  11. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41.
  12. Lin AM, Rini BI, Small EJ. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10.
  13. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California